Axsome Therapeutics (AXSM) Assets Average (2016 - 2026)

Axsome Therapeutics' Assets Average history runs 11 years deep, the most recent figure standing at $701.7 million for Q1 2026.

• In Q1 2026, Assets Average rose 20.45% year-over-year to $701.7 million; the TTM figure through Mar 2026 stood at $701.7 million (up 20.45% YoY), while the FY2025 annual figure was $629.2 million, up 8.78% from the prior year.
• Assets Average came in at $701.7 million for Q1 2026 at Axsome Therapeutics, up from $679.5 million in the prior quarter.
• In the past five years, Assets Average ranged from a high of $701.7 million in Q1 2026 to a low of $88.2 million in Q1 2022.
• A 5-year average of $491.2 million and a median of $565.0 million in 2024 frame the typical range for Assets Average.
• Across the five-year window, Assets Average sank 50.05% in 2022 and surged 308.66% in 2023, its largest moves.
• Axsome Therapeutics' Assets Average stood at $335.2 million in 2022, then soared by 77.36% to $594.5 million in 2023, then fell by 4.97% to $565.0 million in 2024, then climbed by 20.28% to $679.5 million in 2025, then gained by 3.26% to $701.7 million in 2026.
• According to Business Quant data, Assets Average over the past three periods registered $701.7 million, $679.5 million, and $654.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison